Therapeutic Response

EGFR activating variants status confers therapeutic sensitivity to Erlotinib in combination with Ramucirumab in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Cyramza (ramucirumab) [product information]. EMA. The European Medicines Agency (EMA) has authorized ramucirumab in combination with erlotinib as a first-line treatment for adult patients with metastatic non-small cell lung cancer with activating EGFR variants.